



Online article and related content
current as of May 11, 2010.

Diagnosing and Managing Common Food Allergies: A Systematic Review

Jennifer J. Schneider Chafen; Sydne J. Newberry; Marc A. Riedl; et al.

JAMA. 2010;303(18):1848-1856 (doi:10.1001/jama.2010.582)

<http://jama.ama-assn.org/cgi/content/full/303/18/1848>

Supplementary material

eSupplement

<http://jama.ama-assn.org/cgi/content/full/303/18/1848/DC1>

Correction

[Contact me if this article is corrected.](#)

Citations

[Contact me when this article is cited.](#)

Topic collections

Dermatology; Dermatologic Disorders; Public Health; Hypersensitivity; Review; Diagnosis; Diet; Immunology; Allergy

[Contact me when new articles are published in these topic areas.](#)

CME course

[Online CME course available.](#)

CME course

[Online CME course available.](#)

Subscribe

<http://jama.com/subscribe>

Permissions

permissions@ama-assn.org

<http://pubs.ama-assn.org/misc/permissions.dtl>

Email Alerts

<http://jamaarchives.com/alerts>

Reprints/E-prints

reprints@ama-assn.org

Diagnosing and Managing Common Food Allergies

A Systematic Review

Jennifer J. Schneider Chafen, MD, MS

Sydne J. Newberry, PhD

Marc A. Riedl, MD

Dena M. Bravata, MD, MS

Margaret Maglione, MPP

Marika J. Suttrop, MS

Vandana Sundaram, MPH

Neil M. Paige, MD, MSHS

Ali Towfigh, MD

Benjamin J. Hulley, BS

Paul G. Shekelle, MD, PhD

FOOD ALLERGIES HAVE SIGNIFICANT deleterious effects on family economics, social interactions, school and work attendance, and health-related quality of life.^{1,2} However, currently licensed treatments target only the symptoms of reactions and anaphylaxis, not the allergies themselves.

Food allergies are heterogeneous in terms of both their underlying pathophysiology (eg, mediated via both IgE and non-IgE immunologic pathways) and their clinical manifestations (ranging from mild rashes to life-threatening anaphylaxis). The literature on food allergies lacks a clear consensus regarding the most effective diagnostic and management approaches to even the most common conditions.

Under contract from the National Institute of Allergy and Infectious Diseases (NIAID) and in support of ongoing work to produce clinical practice

See also Patient Page.



CME available online at
www.jamaarchivescme.com
and questions on p 1871.

Context There is heightened interest in food allergies but no clear consensus exists regarding the prevalence or most effective diagnostic and management approaches to food allergies.

Objective To perform a systematic review of the available evidence on the prevalence, diagnosis, management, and prevention of food allergies.

Data Sources Electronic searches of PubMed, Cochrane Database of Systematic Reviews, Cochrane Database of Abstracts of Reviews of Effects, and Cochrane Central Register of Controlled Trials. Searches were limited to English-language articles indexed between January 1988 and September 2009.

Study Selection Diagnostic tests were included if they had a prospective, defined study population, used food challenge as a criterion standard, and reported sufficient data to calculate sensitivity and specificity. Systematic reviews and randomized controlled trials (RCTs) for management and prevention outcomes were also used. For foods where anaphylaxis is common, cohort studies with a sample size of more than 100 participants were included.

Data Extraction Two investigators independently reviewed all titles and abstracts to identify potentially relevant articles and resolved discrepancies by repeated review and discussion. Quality of systematic reviews and meta-analyses was assessed using the AMSTAR criteria, the quality of diagnostic studies using the QUADAS criteria most relevant to food allergy, and the quality of RCTs using the Jadad criteria.

Data Synthesis A total of 12 378 citations were identified and 72 citations were included. Food allergy affects more than 1% to 2% but less than 10% of the population. It is unclear if the prevalence of food allergies is increasing. Summary receiver operating characteristic curves comparing skin prick tests (area under the curve [AUC], 0.87; 95% confidence interval [CI], 0.81-0.93) and serum food-specific IgE (AUC, 0.84; 95% CI, 0.78-0.91) to food challenge showed no statistical superiority for either test. Elimination diets are the mainstay of therapy but have been rarely studied. Immunotherapy is promising but data are insufficient to recommend use. In high-risk infants, hydrolyzed formulas may prevent cow's milk allergy but standardized definitions of high risk and hydrolyzed formula do not exist.

Conclusion The evidence for the prevalence and management of food allergy is greatly limited by a lack of uniformity for criteria for making a diagnosis.

JAMA. 2010;303(18):1848-1856

www.jama.com

Author Affiliations: VA Palo Alto Healthcare System, Palo Alto, California (Dr Chafen and Ms Sundaram); Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, California (Drs Chafen and Bravata, and Ms Sundaram); Southern California Evidence Based Practice Center, Rand Health, Santa Monica, California (Drs Newberry, Paige, Towfigh, and Shekelle, and Mss Maglione and Suttrop and Mr Hulley); Clinical Immunology and Allergy, University of California Los Angeles—David Geffen School of Medicine, Los Angeles (Dr Riedl); and West Los Angeles VA Medical

Center, Los Angeles, California (Drs Paige, Towfigh, and Shekelle).

Corresponding Author: Jennifer J. Schneider Chafen, MD, MS, Center for Primary Care and Outcomes Research, Stanford University School of Medicine, 117 Encina Commons, Stanford, CA 94305-6019 (jjschnei@stanford.edu).

Clinical Review Section Editor: Mary McGrae McDermott, MD, Contributing Editor. We encourage authors to submit papers for consideration as a Clinical Review. Please contact Mary McGrae McDermott, MD, at mdm608@northwestern.edu.

guidelines, we reviewed the available evidence on the prevalence, diagnosis, management, and prevention of food allergies.³ This review presents our findings for the most common allergenic foods: cow's milk, hen's egg, peanut, tree nut, fish, and shellfish, which account for more than 50% of all allergies to food.⁴

METHODS

Literature Search and Study Selection

We searched 4 electronic databases: PubMed, Cochrane Database of Systematic Reviews, Cochrane Database of Abstracts of Reviews of Effects, and Cochrane Central Register of Controlled Trials (eAppendix, available at <http://www.jama.com>). We restricted searches to English-language articles between January 1988 and September 2009; however, we included older articles identified via reference mining or expert input. *Food allergy* is not a Medical Subject Headings (MeSH) term; therefore, the search terms included the MeSH term *food hypersensitivity*, text words such as *food allerg**, and terms for foods and conditions such as *cow milk*, *peanut*, *asthma*, *oral allergy syndrome*, and *anaphylaxis*.

Our initial inclusion criteria were broad and included prior systematic reviews, meta-analyses, or both, and studies presenting original data related to the prevalence, diagnosis, management, or prevention of food allergy. After assessing the relative quantities of studies on these topics, we restricted studies of prevalence to those with population-based samples (and systematic reviews of such studies); studies of diagnostic tests to those that presented sufficient data to calculate both sensitivity and specificity, had a prospective, defined study population, and used food challenge as a criterion standard; and studies of management and prevention to those that were either controlled trials (both randomized and nonrandomized) or systematic reviews. For food allergies where anaphylaxis is disproportionately common (eg, shellfish, fish, or peanut), we included cohort studies with a sample size of more than 100 participants. Complete inclusion and exclusion criteria are available in our evidence report.³

Data Abstraction

Two investigators (S.J.N. and P.G.S.) independently reviewed all titles and abstracts to identify potentially relevant articles. We independently abstracted articles that met inclusion criteria and resolved discrepancies by repeated review and discussion. The principal investigator (P.G.S.) served as the arbiter for conflict resolution. If 2 or more studies presented the same data from a single patient population, we included these data only once in our analysis.

Quality Assessment

We assessed the quality of systematic reviews and meta-analyses using the AMSTAR criteria, the quality of diagnostic studies using the QUADAS criteria most relevant to food allergy, and the quality of randomized controlled trials (RCTs) using the Jadad criteria.⁵⁻⁸ For studies on prevalence, we evaluated quality based on the criterion standard used for diagnosis, evaluation of a population-based sample, and participation rate. For management studies, we initially considered all observational studies to be of poor quality but then upgraded the rating to good if the study had a high level of follow-up ($\geq 90\%$), large sample size (> 500 patients), and made attempts to reduce bias either through study design or statistical analysis.

Data Synthesis

For prevalence studies, we reported the literature estimates. The heterogeneity of management and prevention studies prevented data pooling; therefore, we summarized those data narratively.

For diagnostic studies, we examined the distribution of sensitivity and specificity pairs by food allergy, test type, and food allergy $\times$ test type. We calculated summary receiver operator characteristic (ROC) curves by transforming sensitivity and specificity pairs (weighted by sample size) using logistic transforms and regressing logit sensitivities on logit specificities.⁹ Summary ROC curves were calculated by back transforming predicted values from these regression models. We calculated the 95% confidence interval (CI) for the summary ROC

curves by reestimating the curves on bootstrap samples. The bootstrap was also used to test differences in areas under the curves for subsets of the studies. The bootstrap incorporated the clustering of observations within studies by resampling at the study level rather than the sensitivity-specificity pair level. These analyses were performed with Stata version 10.0 (StataCorp LP, College Station, Texas).

RESULTS

Our searches identified 12 378 titles, of which 1216 articles underwent full text review and 182 studies met inclusion criteria for allergies to any food (eFigure 1). Our review is restricted to the 72 studies that reported data on food allergies to cow's milk, hen's egg, peanut, tree nut, fish, and shellfish. These studies included 1 meta-analysis on incidence and prevalence; 18 studies on diagnosis; and 53 studies on management and prevention (28 studies on management, 4 meta-analyses, and 21 studies on prevention).

Definition of Food Allergy

Food allergy has no universally accepted definition. The NIAID has suggested that food allergy be defined as an "adverse immune response that occurs reproducibly on exposure to a given food and is distinct from other adverse responses to food, such as food intolerance, pharmacologic reactions, and toxin-mediated reactions."³ To assess agreement with this definition, we retrieved 85 reviews of food allergy, 73 of which did not otherwise meet inclusion criteria (eReferences). Seventy-one of these articles (82%) provided a definition of *food allergy*. Generally, definitions overlapped considerably with the NIAID definition: 62 reviews (87%) included the phrase *immune response*, 22 (31%) included the concept of reproducibility, 32 (45%) included the concept of a particular food, and 35 (49%) required distinction from food intolerance, pharmacologic, or toxin-mediated reactions. Furthermore, 56 reviews (79%) stated that food allergy involved IgE-mediated reac-

tions and 47 (66%) included non-IgE-mediated immunologic reactions.

Prevalence of Food Allergies

We identified an existing systematic review on the prevalence of food allergies⁴ that identified 51 relevant studies that provided population-based estimates of prevalence. Studies varied in how food allergy was diagnosed. Some used self-report, other studies used skin prick testing (SPT) or food-specific IgE determinations, and a few studies used double-blind, placebo-controlled food challenges. In general, studies that used self-report found a higher prevalence of food allergies than studies that used the other 3 methods. For cow's milk allergy, the pooled estimate of prevalence was 3.5% (95% CI, 2.9%-4.1%) from self-report and 0.6% to 0.9% from the other 3 methods. For the other common foods, the pooled estimates for self-report and other methods were for egg allergies, 1.3% (95% CI, 1.0%-1.6%) vs 0.3% to 0.9%; for peanut allergies, 0.75% (95% CI, 0.6%-0.9%) vs 0.75%; for fish allergies, 0.6% (95% CI, 0.5%-0.7%) vs 0.2% to 0.3%; and for shellfish allergies, 1.1% (95% CI, 1.0%-1.2%) vs 0.6%. The authors noted that the precision of these latter estimates was very poor and that more standardized methods for diagnosis are needed to minimize this source of variability across studies. The self-reported prevalence of allergy to cow's milk and hen's egg (but not peanut, fish, or shellfish) was higher in children than in adults.

Changes in the Prevalence of Food Allergies

We identified 3 population-based studies (1 each from the United States, Canada, and the United Kingdom) that assessed whether food allergies are changing over time.¹⁰⁻¹⁴ The parentally-reported prevalence of peanut allergy among children living on the Isle of Wight increased from 0.5% in 1989 to 1.0% in 1994-1996 ($P=.20$), and the prevalence of IgE antibodies increased from 1.1% to 3.3% ($P=.001$).¹⁰ A response rate of 43% in the 1994-1996 sample is a limitation of this study. The prevalence of peanut allergy among schoolchildren in Montreal (assessed using an algorithm that included

parental self-report, SPT, food-specific IgE, and food challenge) was 1.5% in 2000-2002 and increased to 1.63% in 2005-2007, a difference that was not statistically significant.^{11,12} The authors noted that the width of the CIs on these estimates prevented identifying the true change in prevalence. The US studies used administrative data from hospital discharges, self-report, and food-specific IgE to estimate changes in food allergy prevalence over time and estimated that 3.3% of US children had food allergies in 1997 vs 3.9% in 2007, a statistically significant difference.^{13,14} However, these authors noted that this increase could be due to increased awareness and reporting rather than a true increase in disease.

Diagnosis of Food Allergies

There are no well-accepted criteria for diagnosing food allergies. Numerous diagnostic tests have been proposed as useful adjuncts to the clinical history for establishing the diagnosis. The most commonly studied are SPT, serum food-specific IgE determinations, and atopy patch testing (APT), although APT is not in widespread clinical use. The placebo-controlled food challenge is usually considered the criterion standard. Most authorities consider it necessary to perform the food challenge under double-blind conditions, although at least 1 study has shown that open challenges give the same results.¹⁵ Unfortunately, the need for specialized personnel, time, expense, risk of anaphylaxis, and lack of criteria for what constitutes a positive food challenge limits the widespread use of this test.

We identified 18 studies of diagnostic tests that were prospective, had an identified patient population, compared SPT, serum food-specific IgE, or APT with a food challenge reference standard, and reported both sensitivity and specificity (TABLE).¹⁵⁻³² In general, the quality of these studies was fair (eFigure 2). Of these studies, 13 studied SPT,^{15,17-24,29-32} 11 studied serum food-specific IgE,^{16,18,20-26,29,31} and 8 studied APT.^{15,18,20,22,24,25,27,28} The FIGURE presents the summary ROC curves comparing SPT and serum food-specific IgE to a food challenge overall, and separately for cow's milk and

hen's egg. There were no statistically significant differences for the diagnostic tests overall or for the specific foods. There were insufficient data to calculate summary ROC curves for the APT or for peanut or tree nut or fish or shellfish allergies. Ten studies attempted to improve diagnostic accuracy by combining tests, but results were generally inconclusive.³ Other proposed tests for diagnosing food allergy (eg, histamine, tryptase, and chymase assays) were either not assessed or had too few studies meeting inclusion criteria to allow conclusions regarding their use for diagnosing food allergies.

Management of Food Allergies

We identified 25 studies of 7 food allergy management strategies³³⁻⁵⁷ (elimination diets [1 study³³]; immunotherapy [7 studies³⁴⁻⁴⁰]; food substitutions or alterations [8 studies⁴¹⁻⁴⁸]; diets in breastfeeding women [1 study⁴⁹]; medical or pharmacologic therapies [5 studies⁵⁰⁻⁵⁴]; probiotics [2 studies^{55,56}]; and education [1 study⁵⁷]) (eTable 1). Overall study quality was fair. The variability of the studies did not allow for pooling of results or for a clear consensus regarding the most effective management strategies.

Elimination Diets. Only 1 study³³ evaluated the effects of an elimination diet and reported improvement in atopic dermatitis in patients on elimination diets compared with those who were not on elimination diets.

Immunotherapy. In immunotherapy, the immune response to allergen exposure is altered using protocols designed to administer increasing doses of the causative allergen over time. Immunotherapy may result in desensitization or tolerance to the specific allergen. Desensitization refers to a temporary clinical state in which allergen exposure fails to cause allergic symptoms, whereas tolerance indicates clinical nonreactivity to allergen exposure even after long periods of abstinence. Five studies gave oral immunotherapy^{34-36,38,39} and 2 studies gave subcutaneous immunotherapy.^{37,40} Immunotherapy was somewhat effective for desensitization but tolerance and safety were inadequately evaluated.

Food Substitutions or Alterations. Five studies⁴¹⁻⁴⁵ reported feeding infants with presumed cow's milk allergy with alternatives to cow's milk formula.

These studies did not present sufficient data to conclude which formula was most beneficial. Three studies⁴⁶⁻⁴⁸ treated cow's milk allergy by substituting non-

cow's milk, but methodological limitations of these studies prevent conclusive determination of the benefits of these substitutes for cow's milk.

Table. Studies of Diagnosis of Food Allergies

Source	Population	Reference Test	Diagnostic Tests Used	Foods Evaluated				
				CM	HE	P	F	O
Sampson, ¹⁶ 2001	100 consecutive children (ages 0.4-14.3 y)	FC	slgE: Pharmacia CAP-FEIA	✓	✓	✓	✓	✓
Wananukul, ¹⁷ 2005	100 consecutive patients with urticaria, university hospital pediatric dermatology clinic in Bangkok over 2 y	DBPCFC or OFC in 22 patients, recent history of anaphylactic reaction (n = 5)	SPT: cutoff not reported	✓	✓		✓	✓
Mehl, ¹⁸ 2006	437 German consecutive children (3 mo-17 y), specialist for suspected food allergy; 391 patients with AD	DBPCFC (except patients <1 y with history of immediate reactions) guided by SPT, slgE, and clinical history	SPT: fresh food samples, positive tests not reported; slgE: RAST APT: 1 drop fresh CM/HE (white and yolk) put on filter paper and applied to back with aluminum cups; occlusion time 48 h; results at 48 and 72 h	✓	✓			✓
Calvani, ¹⁹ 2007	104 consecutive children, Italian pediatric allergy clinic for suspected CMA	FC (70 OFC and 34 DBPCFC): 28/104 positive tests	SPT: lactalbumin, casein, BLG, and fresh milk; positive tests defined as mean wheal diameters 3 mm ≥ negative control	✓	✓			
Canani, ²⁰ 2007	60 children (3-48 mo), pediatric gastroenterology center in Naples for suspected food allergy-related symptoms	OFC with fresh CM, HE, or wheat powder based on reactions to SPT, APT, and slgE (31/55 OFC positive for CM; 19/28 OFC positive for HE)	SPT: positive reaction ≥3 mm with no reaction to control APT: occlusion time 48 h; results at 72 h; positive test defined as minimum of erythema and slight infiltration	✓	✓			✓
Osterballe, ²¹ 2004	495 children, Danish birth cohort (3 y) with and without AD	OFC to assess both early and late reactions (3/8 positive for CM; 8/14 positive for HE)	SPT: cutoff ≥3mm Magic Lite: cutoff 1.43 U/mL	✓	✓			
Isolaure, ¹⁵ 1996	183 Finnish children (2-36 mo) with AD and suspected CMA	DBPCFC (n = 118) or OFC (n = 65); 99/183 confirmed with CMA by oral challenge	SPT: commercial CM allergen and milk powder; reactions at 15 min; wheals >half the histamine reaction size were positive APT: humidified skim CM applied with aluminum cups; occlusion time 48 h; results at 48 and 72 h	✓				
Keskin, ²² 2005	37 consecutive children (1.5-84 mo) with suspected CMA, Turkish allergy clinic at a tertiary care center, excluding children with chronic disease	DBPCFC preceded by ≥2 wk of CM elimination (except 6 patients with anaphylactic reaction to CM); reactions were categorized as early (within 2 h of test) or late (23/37 had positive challenges or history of anaphylaxis)	SPT: commercial allergen with wheal ≥3 mm larger than negative control was positive slgE: Immuno CAP-FEIA APT: CM powder mixed with saline, applied with aluminum cups; cups removed after 48 h; read 72 h after application	✓				
García-Ara, ²³ 2001	170 consecutive infants (1-12 mo), Madrid children's hospital allergy service for suspected CMA	OFC (n = 161 infants), remaining 9 had severe allergic reaction to CM protein and evidence of milk slgE	SPT: ALA, BLG, whole milk, and casein; positive test defined as a net wheal diameter 3 mm > negative control slgE: CAP-FEIA using milk, ALA, BLG, and casein; positive test defined as slgE ≥0.35	✓				
Saarienen, ²⁴ 2001	239 infants (6-7 mo), prospective Finnish birth cohort study, effect of infant formula on CMA with symptoms that disappeared on withdrawal of milk	239 OFC (118/239 positive)	SPT: CM formula, whole milk, or CM protein fractions; positive test was defined as wheal diameter ≥3 mm slgE: CAP using whole CM and/or CM protein fractions APT: CM formula powder, bovine serum albumin, crystallized bovine BLG, and bovine casein each dissolved in saline; filter papers soaked in solutions before applied to back under aluminum cup; occlusion time 48 h; results at 48 h	✓				
De Boissieu, ²⁵ 2003	35 children (2-57 mo), diagnosis of nonspecific persistent digestive symptoms	FC	slgE: CAP-RAST APT: blotting paper soaked with 50% skimmed CM applied to uninvolved skin on back with aluminum cup; occlusion time 48 h; results at 48 and 72 h	✓				
Tainio, ²⁶ 1990	34 children (3-51 mo) with suspected CMA	Elimination diet and FC (19 confirmed with FC)	slgE: RAST	✓				
Cudowska, ²⁷ 2005	34 children (5 mo-16 y), 20 (<3 y), and 14 (≥3 y) with suspected CMA	FC	APT: isotonic saline mixed with CM powder and applied to skin on back with aluminum cup; occlusion time 48 h; results at 48 and 72 h	✓				

(continued)

Table. Studies of Diagnosis of Food Allergies (continued)

Source	Population	Reference Test	Diagnostic Tests Used	Foods Evaluated				
				CM	HE	P	F	O
Järvinen, ²⁸ 2003	90 children (2.5-36 mo) with CMA controlled via elimination but with residual symptoms not responding to elimination of eggs, nuts, fruits, chocolate, or fish	Elimination diet then OFC; immediate reactions were within 1 h of last dose; each child only tested with 1 cereal (30/44 OFC were positive for wheat; 66/90 OFC were positive for all cereals)	APT: wheat flour mixed with isotonic saline applied to back with aluminum cups; cups removed after 48 h and reactions at 72 h after cups were applied; presence of edema or eczema were positive reaction	✓				✓
Monti, ²⁹ 2002	107 children (1-19 mo) with AD and no prior egg exposure, Italian allergy clinic for AD	OFC and monitoring for early and late reactions (<8 d) (72/107 children were positive)	SPT: commercial extracts of albumin and yolk; reported absolute measure of the wheal diameter slgE: RAST		✓			
Diéguez, ³⁰ 2008	104 patients (12-15 mo) with IgE-mediated CMA (by history and SPT/slge) with no prior egg exposure, Spanish allergy clinic	OFC with egg components (38/104 were positive)	SPT: egg white, yolk, OVA, OVM, OVT, and lysozyme; wheal diameter ≥3 mm regarded as positive		✓			
Rancé, ³¹ 2002	393 consecutive children, French hospital with suspected peanut allergy	DBPCFC preceded by elimination diet; patients monitored for reactions for 4 h following test (177/393 peanut allergic by FC)	SPT: fresh peanut mix with wheals 3 mm >negative control defined as positive slgE: Pharmacia CAP-FEIA			✓		
Wainstein, ³² 2007	84 consecutive children, Sydney pediatric hospital allergy clinic with positive SPT (defined as a wheal 3 × 3 mm > control)	DBPCFC or documented recent reaction to peanut (51/84 peanut allergic by FC)	SPT: commercial whole peanut extract; 2 wheal diameter cutoffs of ≥8 and ≥15 mm used to calculate sensitivity and specificity			✓		

Abbreviations: AD, atopic dermatitis; ALA, alpha-lactalbumin; APT, atopy patch test; BLG, beta-lactoglobulin; CAP-FEIA, fluorezymeimmunoassay; CAP-RAST, radioallergosorbic test; CM, cow's milk; CMA, cow's milk allergy; DBPCFC, double-blind, placebo-controlled food challenge; F, shellfish/fish; FC, food challenge; HE, hen's egg; O, other; OFC, open food challenge; OVA, ovalbumin; OVM, ovomucoid; OVT, ovotransferrin; P, peanut/tree nut; RAST, radioallergosorbic test; slgE, serum food-specific IgE; SPT, skin prick test.

Diets in Breastfeeding Women. One study⁴⁹ evaluated hypoallergenic diets in nursing women to reduce food allergy-related colic in their children and found a statistically significant improvement in the low allergen group, with an adjusted relative risk of 37% (95% CI, 18%-56%).

Medical or Pharmacologic Therapies. An elimination diet combined with either thymomodulin⁵⁰ or cromolyn⁵¹ appeared to improve food allergy-related skin lesions, whereas cromolyn without an elimination diet did not.⁵² Two studies^{53,54} evaluated pharmacologic management of peanut or tree nut allergy. One study⁵³ found that a 450-mg dose of TNX-901, a humanized IgG1 monoclonal antibody, increased the sensitivity from one-half a peanut to almost 9 peanuts, and the other study⁵⁴ found that azemazole decreased symptom severity in an oral provocation test.

Probiotics. Probiotics did not improve atopic dermatitis outcomes, either standardized measures of disease severity or rectal bleeding, in infants with suspected food allergies.^{55,56}

Education. After giving patients with a peanut allergy advice on nut avoidance and self-recognition of reactions, 1 study⁵⁷ found 88 of 567 patients (15%) had a follow-up reaction of reduced severity and 3 of 567 patients (0.5%) had a severe follow-up reaction compared with an initial 12% of patients.

Prevention of Food Allergies and Atopic Eczema

In general, studies addressing food allergy prevention outcomes enrolled pregnant women, their newborns, or both with a history of allergic disease and randomized them to receive special diets (or formula) or receive placebo (to be given with or without breast milk), and followed up the children to compare the cumulative incidence of allergic disease in the intervention and placebo groups. We identified 6 systematic reviews⁵⁸⁻⁶³ and 47 RCTs^{33,64-109} that evaluated methods to prevent food allergies. Twenty of the included RCTs were evaluated in 1 or more of these systematic reviews and were not analyzed further.⁶⁴⁻⁸³ Two publications^{84,85} reporting information on the

same population were excluded because they did not report data comparing the intervention and control groups. We also excluded studies by Chandra et al⁶⁵, given published reports that question the validity of those data.^{87,88} The studies meeting inclusion criteria evaluated 5 prevention strategies: breastfeeding and delayed introduction of solids (2 studies^{89,90}), maternal diet during pregnancy or lactation (3 studies^{58,91,92}), exclusive breastfeeding (3 studies^{93,95,110}), special diets in infants and young children (12 studies^{59-61,94,96-100,106-108}), and probiotics (5 studies¹⁰¹⁻¹⁰⁵) (eTable 2).

Breastfeeding and Delayed Introduction of Solids. Both of the included studies found some association between delayed solids and incidence of atopic symptoms (parents reported decreased food intolerance⁸⁹ and nonsignificant higher incidence of atopy in controls⁹⁰). However, their findings should be interpreted with caution given the multimodal nature⁸⁹ and poor quality.⁹⁰

Maternal Diet During Pregnancy or Lactation. Maternal diet during preg-

nancy, lactation, or both demonstrated conflicting effects on atopic disease among children at high risk. One systematic review⁵⁸ reported no evidence to support a protective effect of maternal diet; 2 studies^{91,92} reporting on 1 nonrandomized comparative study (115 patients evaluated at 10 months and at 4 years) found a significantly reduced incidence of atopic dermatitis in children whose mothers had a restricted diet during lactation (free from cow's milk, hen's egg, and fish product for 3 months' postpartum).

Exclusive Breastfeeding. Three analyses^{93,95,110} of data from the same population provided conflicting evidence on the prevention of atopic disease by exclusive breastfeeding, depending on which control group was used (2 of these studies reported decreased atopic dermatitis among children who were exclusively breastfed compared with children who were not).

Special Diets in Infants. Hydrolyzed formulas, soy formulas, and early exposure to cow's milk have been tested for prevention of allergy development. Two systematic reviews^{60,61} and 5 RCTs⁹⁶⁻¹⁰⁰ evaluated the effects of hydrolyzed formulas on the development of food aller-

gies in children. The effects of soy formula were evaluated by 1 systematic review⁵⁹ and 1 RCT.⁹⁴ Three RCTs¹⁰⁶⁻¹⁰⁸ evaluated neonatal exposure to cow's milk on 2 distinct populations.

Hydrolyzed formulas (particularly extensively and partially hydrolyzed formulas) may reduce infant and childhood cow's milk allergy in high-risk infants when compared with cow's milk formula. However, the terms *partially* and *extensively* hydrolyzed as well as *high risk* were not well-defined in the literature. There was little difference between soy formula and cow's milk formula for the prevention of allergies in high-risk infants. The benefits and harms of early exposure to cow's milk remain uncertain.

Probiotics. Two studies^{101,102} evaluated probiotics in combination with breastfeeding, and 3 studies¹⁰³⁻¹⁰⁵ evaluated probiotics in pregnant women and their newborn infants. The use of probiotics in the perinatal period may be associated with mild reductions in the cumulative incidence of allergic skin disease in children. However, these results are interpreted with caution because the trials with the most significant results used

probiotics in conjunction with breastfeeding, hypoallergenic formula, or both, and the independent effects of probiotics could not be established.


COMMENT

This systematic review of food allergies found that the evidence on the prevalence, diagnosis, management, and prevention of food allergies is voluminous, diffuse, and critically limited by the lack of uniformity for the diagnosis of a food allergy, severely limiting conclusions about best practices for management and prevention.

Our review found several key results. First, food allergies affect more than 1% or 2% but less than 10% of the US population. Whether the prevalence of food allergies is increasing is not well established. Second, food challenges, SPT, and serum food-specific IgE all have a role to play in making the diagnosis but no one test has sufficient ease of use or sensitivity or specificity to be recommended over the other tests. Numerous other proposed diagnostic tests are of uncertain value due to lack of evidence.

Third, although elimination diets are the mainstay of therapy, we identified

Figure. Summary ROC Curves for the Diagnosis of All Food Allergies, Cow's Milk Allergy, and Hen's Egg Allergy Comparing SPT With sIgE Testing



ROC indicates receiver operator characteristic; SPT, skin prick testing; sIgE, serum food-specific IgE. Each of the individual circles represents the sensitivity/specificity pair from an individual study. More than 1 data point may be shown for each study due to a study reporting multiple thresholds for sensitivity/specificity. For all food allergies, the area under the curve for SPT and sIgE was 0.87 (95% confidence interval [CI], 0.81-0.93) and 0.84 (95% CI, 0.78-0.91), respectively (mean difference, 0.03; 95% CI, -0.05 to 0.11). For cow's milk allergy, 0.84 (95% CI, 0.75-0.92) and 0.78 (95% CI, 0.70-0.86), respectively (mean difference, 0.06; 95% CI, -0.06 to 0.18). For hen's egg allergy, 0.87 (95% CI, 0.76-0.97) and 0.85 (95% CI, 0.62-1.09), respectively (mean difference, 0.01; 95% CI, -0.25 to 0.27).

only 1 RCT of an elimination diet. Many authorities would consider RCTs of elimination diets for serious life-threatening food allergy reactions unnecessary and unethical; however, it should be recognized that such studies are generally lacking for other potential food allergic conditions, such as atopic dermatitis and eosinophilic esophagitis. In these instances, the benefits of an elimination diet are uncertain based on published evidence, and potential benefits need to be weighed against the potential nutritional risks of such a diet, particularly in children. More controlled studies of elimination diets in patients with non-anaphylactic food allergy symptoms are needed.

Fourth, immunotherapy, although currently not a licensed method for the treatment of food allergy, may be effective in generating desensitization, but whether this treatment can also generate long-term tolerance remains to be determined. The safety of immunotherapy is likely to vary with the food allergen and the route of therapy administration (eg, oral, sublingual) and, to date, it has been inadequately studied.

Fifth, among high-risk infants, hydrolyzed formula may prevent against cow's milk allergy but standardized definitions of *high risk* and *hydrolyzed formula* do not exist. Probiotics in conjunction with breastfeeding, hypoallergenic formula, or both may help prevent food allergy but their independent effects remain unclear.

A clinical consequence of our findings regarding lack of uniformity of criteria for diagnosis and the limited sensitivity and specificity of existing office-based tests for IgE sensitization is the potential for overdiagnosis of food allergy in the general population. Patients with nonspecific symptoms (rash, abdominal complaints) who have positive SPT or serum food-specific IgE studies to foods have less than a 50% likelihood of actually having a food allergy (given the sensitivity, specificity, and prevalence). Inappropriately diagnosing such individuals with food allergy may unnecessarily subject them to broad dietary restrictions, the risk of

nutritional problems from elimination diets (eg, milk or egg elimination in children), significant anxiety and worry, and the social challenges food allergies cause.¹ Proper interpretation of SPT and serum food-specific IgE results requires evaluation of the data within the context of the clinical history and physician understanding of symptoms consistent with clinical food allergy to separate out false positives from true positives for food allergy. Furthermore, the overdiagnosis or misdiagnosis of food allergy by medical practitioners obscures the substantial morbidity caused in patients truly affected by immune-mediated food allergy and serves to perpetuate some public misperceptions that food allergy is a trivial medical condition.

The limitations of our study reflect the limitations of the included articles in terms of the quality of the original studies. We have attempted to limit our conclusions accordingly. In addition to the need for greater rigor in the design, execution, and reporting of food allergy studies, a key limitation of these studies is the heterogeneity in the criteria used for the diagnosis of food allergy. This makes comparisons of prevalence across studies dependent on the methods used for the diagnosis, limits all studies of diagnostic tests by the lack of a consistent criterion standard, and introduces heterogeneity into studies of management, making comparisons across studies more challenging. Another key limitation of our analysis was that we were unable to perform formal evaluations for publication bias due to the heterogeneity of the included studies. The potential for publication bias may be magnified in a review of food allergy, because *food allergy* is not a PubMed index term, and there is no good agreement on the conditions that constitute a food allergy. This makes searching for the relevant literature particularly challenging. Consideration should be given to creating a *food allergy* index term to facilitate future searches for relevant evidence. Our restriction to

English-language-only articles also may have excluded some relevant studies. Even with these limitations, we screened more than 12 000 citations and reviewed in detail more than 1000 full-text articles. However, food allergy is a subject of much current study. Three abstracts¹¹¹⁻¹¹³ have recently been presented (1 regarding the prevalence in different racial groups of symptoms and serum food-specific IgE sensitization in a nationally-representative US sample¹¹¹ and 2 more on preliminary positive early results of desensitization^{112,113}). We expect the evidence base about food allergy to change more rapidly in the near future than it has in the past.

In conclusion, there is a voluminous literature related to food allergy, but high-quality studies are few. Prime needs for advancement of the field are uniformity in the criteria for what constitutes a food allergy and a set of evidence-based guidelines on which to make this diagnosis.

Author Contributions: Dr Shekelle had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Bravata, Maglione, Shekelle.
Acquisition of data: Newberry, Bravata, Maglione, Paige, Towfigh.

Analysis and interpretation of data: Chafen, Newberry, Riedl, Bravata, Suttrop, Sundaram, Paige, Hulley, Shekelle.

Drafting of the manuscript: Chafen, Bravata, Suttrop, Sundaram, Paige, Towfigh, Hulley, Shekelle.

Critical revision of the manuscript for important intellectual content: Chafen, Newberry, Riedl, Bravata, Maglione, Sundaram, Paige, Hulley, Shekelle.

Statistical analysis: Suttrop, Sundaram, Hulley.

Obtained funding: Maglione, Shekelle.

Administrative, technical, or material support: Chafen, Maglione, Paige.

Study supervision: Riedl, Bravata, Maglione, Shekelle.

Financial Disclosures: None reported.

Funding/Support: This work was funded in part by contract HHSN272200800065C from the National Institutes of Health. This work was commissioned by National Institute of Allergy and Infectious Diseases in support of the development of practice guidelines.

Role of the Sponsors: The National Institutes of Health had a role in designing the scope of the study and in review of intermediate versions of the evidence report from which this manuscript is derived, but had no role in the collection, management, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.

Online-Only Material: eAppendix, eReferences, eFigures 1 and 2, and eTables 1 and 2 are available at <http://www.jama.com>.

Additional Contributions: Matthew Fenton, PhD, and Marshall Plaut, MD (National Institute of Allergy and Infectious Diseases [NIAID]), provided assistance with

the development of search terms, strategies for this systematic review, and comments. Julie Schwaninger, MS (NIAID), and Joshua Boyce, MD, provided comments on the Evidence Report. Jerome Hawkins, BA, Breanne Johnsen, BS, Aneesa Motala, BA, Yee-Wei Lim, PhD, and Elizabeth Roth, MA (Southern California Evidence Based Practice Center, Rand Health, Santa Monica, California), provided contributions to the Evidence Report prepared for NIAID. John Adams, PhD (Southern California Evidence Based Practice Center, Rand Health), provided help constructing the receiver operator characteristic curves.

REFERENCES

- Bollinger ME, Dahlquist LM, Mudd K, et al. The impact of food allergy on the daily activities of children and their families. *Ann Allergy Asthma Immunol*. 2006;96(3):415-421.
- Perry TT, Scurluck AM, Jones SM, Tilford JM. Economic and caregiver impacts of food allergy. Abstract presented at: Annual Meeting of the American Academy of Allergy, Asthma, and Immunology; March 13-17, 2009; Washington, DC. Abstract 113.
- Shekelle P, Maglione M, Riedl M. Food Allergy: Evidence Report. <http://www.rand.org/health/centers/epc/>. Accessed April 8, 2010.
- Rona RJ, Keil T, Summers C, et al. The prevalence of food allergy: a meta-analysis. *J Allergy Clin Immunol*. 2007;120(3):638-646.
- Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR. *BMC Med Res Methodol*. 2007;7:10.
- Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res Methodol*. 2003;3:25.
- Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials. *Control Clin Trials*. 1996;17(1):1-12.
- Lijmer JG, Mol BW, Heisterkamp S, et al. Empirical evidence of design-related bias in studies of diagnostic tests. *JAMA*. 1999;282(11):1061-1066.
- Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports. *Med Decis Making*. 1993;13(4):313-321.
- Grundt J, Matthews S, Bateman B, Dean T, Arshad SH. Rising prevalence of allergy to peanut in children. *J Allergy Clin Immunol*. 2002;110(5):784-789.
- Kagan RS, Joseph L, Dufresne C, et al. Prevalence of peanut allergy in primary-school children in Montreal, Canada. *J Allergy Clin Immunol*. 2003;112(6):1223-1228.
- Ben-Shoshan M, Kagan RS, Alizadehfar R, et al. Is the prevalence of peanut allergy increasing? *J Allergy Clin Immunol*. 2009;123(4):783-788.
- Brnam AM, Lukacs SL. Food allergy among U.S. children: trends in prevalence and hospitalizations. *NCHS Data Brief*. 2008;(10):1-8.
- Brnam AM, Lukacs SL. Food allergy among children in the United States. *Pediatrics*. 2009;124(6):1549-1555.
- Isolaure E, Turjanmaa K. Combined skin prick and patch testing enhances identification of food allergy in infants with atopic dermatitis. *J Allergy Clin Immunol*. 1996;97(1 pt 1):9-15.
- Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. *J Allergy Clin Immunol*. 2001;107(5):891-896.
- Wananukul S, Chatchatee P, Chatproedprai S. Food induced urticaria in children. *Asian Pac J Allergy Immunol*. 2005;23(4):175-179.
- Mehl A, Rolinck-Werninghaus C, Staden U, et al. The atopy patch test in the diagnostic workup of suspected food-related symptoms in children. *J Allergy Clin Immunol*. 2006;118(4):923-929.
- Calvani M, Mauro C, Alessandri C, et al. Correlation between skin prick test using commercial extract of cow's milk protein and fresh milk and food challenges. *Pediatr Allergy Immunol*. 2007;18(7):583-588.
- Canani RB, Ruotolo S, Auricchio L, et al. Diagnostic accuracy of the atopy patch test in children with food allergy-related gastrointestinal symptoms. *Allergy*. 2007;62(7):738-743.
- Osterballe M, Andersen KE, Bindslev-Jensen C. The diagnostic accuracy of the atopy patch test in diagnosing hypersensitivity to cow's milk and hen's egg in unselected children with and without atopic dermatitis. *J Am Acad Dermatol*. 2004;51(4):556-562.
- Keskin O, Tuncer A, Adaloglu G, et al. Evaluation of the utility of atopy patch testing, skin prick testing, and total and specific IgE assays in the diagnosis of cow's milk allergy. *Ann Allergy Asthma Immunol*. 2005;94(5):553-560.
- García-Ara C, Boyano-Martínez T, Díaz-Pena JM, et al. Specific IgE levels in the diagnosis of immediate hypersensitivity to cows' milk protein in the infant. *J Allergy Clin Immunol*. 2001;107(1):185-190.
- Saarienen KM, Suomalainen H, Savilahti E. Diagnostic value of skin-prick and patch tests and serum eosinophil cationic protein and cow's milk-specific IgE in infants with cow's milk allergy. *Clin Exp Allergy*. 2001;31(3):423-429.
- De Boissieu D, Wagué JC, Dupont C. The atopy patch tests for detection of cow's milk allergy with digestive symptoms. *J Pediatr*. 2003;142(2):203-205.
- Tainio VM, Savilahti E. Value of immunologic tests in cow milk allergy. *Allergy*. 1990;45(3):189-196.
- Cudowska B, Kaczmarek M. Atopy patch test in the diagnosis of food allergy in children with atopic eczema dermatitis syndrome. *Rocz Akad Med Białymst*. 2005;50:261-267.
- Järvinen KM, Turpeinen M, Suomalainen H. Concurrent cereal allergy in children with cow's milk allergy manifested with atopic dermatitis. *Clin Exp Allergy*. 2003;33(8):1060-1066.
- Monti G, Muratore MC, Peltrán A, et al. High incidence of adverse reactions to egg challenge on first known exposure in young atopic dermatitis children. *Clin Exp Allergy*. 2002;32(10):1515-1519.
- Diéguez MC, Cerecedo I, Muriel A, et al. Skin prick test predictive value on the outcome of a first known egg exposure in milk-allergic children. *Pediatr Allergy Immunol*. 2008;19(4):319-324.
- Rancé F, Abbal M, Lauwers-Cances V. Improved screening for peanut allergy by the combined use of skin prick tests and specific IgE assays. *J Allergy Clin Immunol*. 2002;109(6):1027-1033.
- Wainstein BK, Yee A, Jelley D, et al. Combining skin prick, immediate skin application and specific-IgE testing in the diagnosis of peanut allergy in children. *Pediatr Allergy Immunol*. 2007;18(3):231-239.
- Agata H, Kondo N, Fukutomi O, Shinoda S, Orii T. Effect of elimination diets on food-specific IgE antibodies and lymphocyte proliferative responses to food antigens in atopic dermatitis patients exhibiting sensitivity to food allergens. *J Allergy Clin Immunol*. 1993;91(2):668-679.
- Staden U, Rolinck-Werninghaus C, Brewe F, et al. Specific oral tolerance induction in food allergy in children. *Allergy*. 2007;62(11):1261-1269.
- Morisset M, Moneret-Vautrin DA, Guenard L, et al. Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. *Eur Ann Allergy Clin Immunol*. 2007;39(1):12-19.
- Skripak JM, Nash SD, Rowley H, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. *J Allergy Clin Immunol*. 2008;122(6):1154-1160.
- Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. *J Allergy Clin Immunol*. 1997;99(6 pt 1):744-751.
- Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy. *J Allergy Clin Immunol*. 2005;116(5):1073-1079.
- Patriarca G, Nucera E, Pollastrini E, et al. Oral specific desensitization in food-allergic children. *Dig Dis Sci*. 2007;52(7):1662-1672.
- Bucher X, Pichler WJ, Dahinden CA, Helbling A. Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. *Allergy*. 2004;59(12):1272-1276.
- Klemola T, Vanto T, Juntunen-Backman K, et al. Allergy to soy formula and to extensively hydrolyzed whey formula in infants with cow's milk allergy. *J Pediatr*. 2002;140(2):219-224.
- Niggemann B, von Berg A, Bollrath C, et al. Safety and efficacy of a new extensively hydrolyzed formula for infants with cow's milk protein allergy. *Pediatr Allergy Immunol*. 2008;19(4):348-354.
- Garzi A, Messina M, Frati F, et al. An extensively hydrolyzed cow's milk formula improves clinical symptoms of gastroesophageal reflux and reduces the gastric emptying time in infants. *Allergol Immunopathol (Madr)*. 2002;30(1):36-41.
- Savino F, Castagno E, Monti G, et al. Z-score of weight for age of infants with atopic dermatitis and cow's milk allergy fed with a rice-hydrolysate formula during the first two years of life. *Acta Paediatr Suppl*. 2005;94(449):115-119.
- Jirapinyo P, Densupsoontorn N, Wongarn R, Thamonsiri N. Comparisons of a chicken-based formula with soy-based formula in infants with cow milk allergy. *Asia Pac J Clin Nutr*. 2007;16(4):711-715.
- Vita D, Passalacqua G, Di Pasquale G, et al. Ass's milk in children with atopic dermatitis and cow's milk allergy: crossover comparison with goat's milk. *Pediatr Allergy Immunol*. 2007;18(7):594-598.
- Iacono G, Cavataio F, Montalto G, et al. Intolerance of cow's milk and chronic constipation in children. *N Engl J Med*. 1998;339(16):1100-1104.
- Salpietro CD, Gangemi S, Briuglia S, et al. The almond milk. *Minerva Pediatr*. 2005;57(4):173-180.
- Hill DJ, Roy N, Heine RG, et al. Effect of a low-allergen maternal diet on colic among breastfed infants. *Pediatrics*. 2005;116(5):e709-e715.
- Cavagni G, Piscopo E, Rigoli E, et al. Food allergy in children: an attempt to improve the effects of the elimination diet with an immunomodulating agent (thymomodulin). *Immunopharmacol Immunotoxicol*. 1989;11(1):131-142.
- Businco L, Cantani A. Food allergy in children: diagnosis and treatment with sodium cromoglycate. *Allergol Immunopathol (Madr)*. 1990;18(6):339-348.
- Burks AW, Sampson HA. Double-blind placebo-controlled trial of oral cromolyn in children with atopic dermatitis and documented food hypersensitivity. *J Allergy Clin Immunol*. 1988;81(2):417-423.
- Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. *N Engl J Med*. 2003;348(11):986-993.
- Bindslev-Jensen C, Vibits A, Stahl Skov P, Weeke B. Oral allergy syndrome: the effect of astemizole. *Allergy*. 1991;46(8):610-613.
- Szajewska H, Gawronska A, Wos H, et al. Lack of effect of Lactobacillus GG in breast-fed infants with rectal bleeding. *J Pediatr Gastroenterol Nutr*. 2007;45(2):247-251.
- Viljanen M, Savilahti E, Hahtela T, et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants. *Allergy*. 2005;60(4):494-500.
- Ewan PW, Clark AT. Long-term prospective observational study of patients with peanut and nut allergy after participation in a management plan. *Lancet*. 2001;357(9250):111-115.

58. Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child. *Cochrane Database Syst Rev*. 2006; 3:CD000133.
59. Osborn DA, Sinn J. Soy formula for prevention of allergy and food intolerance in infants. *Cochrane Database Syst Rev*. 2006;(4):CD003741.
60. Osborn DA, Sinn J. Formulas containing hydrolysed protein for prevention of allergy and food intolerance in infants. *Cochrane Database Syst Rev*. 2006;(4):CD003664.
61. Hays T, Wood RA. A systematic review of the role of hydrolyzed infant formulas in allergy prevention. *Arch Pediatr Adolesc Med*. 2005;159(9):810-816.
62. Bager P, Wohlfahrt J, Westergaard T. Caesarean delivery and risk of atopy and allergic disease. *Clin Exp Allergy*. 2008;38(4):634-642.
63. Koplin J, Allen K, Gurrin L, et al. Is caesarean delivery associated with sensitization to food allergens and IgE-mediated food allergy: a systematic review. *Pediatr Allergy Immunol*. 2008;19(8):682-687.
64. Halken S, Host A, Hansen LG, Osterballe O. Preventive effect of feeding high-risk infants a casein hydrolysate formula or an ultrafiltrated whey hydrolysate formula. *Pediatr Allergy Immunol*. 1993;4(4):173-181.
65. Chandra RK, Puri S, Hamed A. Influence of maternal diet during lactation and use of formula feeds on development of atopic eczema in high risk infants. *BMJ*. 1989;299(6693):228-230.
66. Juvonen P, Mansson M, Andersson C, et al. Allergy development and macromolecular absorption in infants with different feeding regimens during the first three days of life. *Acta Paediatr*. 1996;85(9):1047-1052.
67. Saarinen KM, Juntunen-Backman K, Jarvenpaa AL, et al. Breast-feeding and the development of cows' milk protein allergy. *Adv Exp Med Biol*. 2000;478:121-130.
68. Willems R, Duchateau J, Magrez P, et al. Influence of hypoallergenic milk formula on the incidence of early allergic manifestations in infants predisposed to atopic diseases. *Ann Allergy*. 1993;71(2):147-150.
69. Vandenplas Y, Hauser B, Van den Borre C, et al. The long-term effect of a partial whey hydrolysate formula on the prophylaxis of atopic disease. *Eur J Pediatr*. 1995;154(6):488-494.
70. Nentwich I, Michkova E, Nevala J, Urbanek R, Szepfalusi Z. Cow's milk-specific cellular and humoral immune responses and atopy skin symptoms in infants from atopic families fed a partially (pHF) or extensively (eHF) hydrolyzed infant formula. *Allergy*. 2001;56(12):1144-1156.
71. Lilja G, Dannaeus A, Foucard T, et al. Effects of maternal diet during late pregnancy and lactation on the development of IgE and egg- and milk-specific IgE and IgG antibodies in infants. *Clin Exp Allergy*. 1991; 21(2):195-202.
72. Lovegrove JA, Hampton SM, Morgan JB. The immunological and long-term atopic outcome of infants born to women following a milk-free diet during late pregnancy and lactation: a pilot study. *Br J Nutr*. 1994;71(2):223-238.
73. Lilja G, Dannaeus A, Foucard T, et al. Effects of maternal diet during late pregnancy and lactation on the development of atopic diseases in infants up to 18 months of age: in-vivo results. *Clin Exp Allergy*. 1989;19(4):473-479.
74. Fälth-Magnusson K, Kjellman NI. Allergy prevention by maternal elimination diet during late pregnancy. *J Allergy Clin Immunol*. 1992;89(3):709-713.
75. Burr ML, Limb ES, Maguire MJ, et al. Infant feeding, wheezing, and allergy: a prospective study. *Arch Dis Child*. 1993;68(6):724-728.
76. von Berg A, Koletzko S, Grubl A, et al. The effect of hydrolyzed cow's milk formula for allergy prevention in the first year of life. *J Allergy Clin Immunol*. 2003;111(3):533-540.
77. Halken S, Hansen KS, Jacobsen HP, et al. Comparison of a partially hydrolyzed infant formula with two extensively hydrolyzed formulas for allergy prevention. *Pediatr Allergy Immunol*. 2000;11(3):149-161.
78. Saarinen KM, Juntunen-Backman K, Jarvenpaa AL, et al. Supplementary feeding in maternity hospitals and the risk of cow's milk allergy. *J Allergy Clin Immunol*. 1999;104(2 pt 1):457-461.
79. Vandenplas Y, Hauser B, Van den Borre C, Sacre L, Dab I. Effect of a whey hydrolysate prophylaxis of atopic disease. *Ann Allergy*. 1992;68(5):419-424.
80. Zeiger RS, Heller S, Mellon MH, et al. Effect of combined maternal and infant food-allergen avoidance on development of atopy in early infancy. *J Allergy Clin Immunol*. 1989;84(1):72-89.
81. Marini A, Agosti M, Motta G, Mosca F. Effects of a dietary and environmental prevention programme on the incidence of allergic symptoms in high atopic risk infants. *Acta Paediatr Suppl*. 1996;414:1-21.
82. Chandra RK, Puri S, Suraiya C, Cheema PS. Influence of maternal food antigen avoidance during pregnancy and lactation on incidence of atopic eczema in infants. *Clin Allergy*. 1986;16(6):563-569.
83. Cant AJ, Bailes JA, Marsden RA, Hewitt D. Effect of maternal dietary exclusion on breast fed infants with eczema: two controlled studies. *Br Med J (Clin Res Ed)*. 1986;293(6541):231-233.
84. Pöysä L, Remes K, Korppi M, Launiala K. Compliance with a dietary manipulation programme in families with infants prone to atopy. *Acta Paediatr Scand*. 1988;77(4):563-568.
85. Pöysä L, Korppi M, Remes K, Juntunen-Backman K. Atopy in childhood and diet in infancy. *Allergy Proc*. 1991;12(2):107-111.
86. Simons FE. Prevention of acute urticaria in young children with atopic dermatitis. *J Allergy Clin Immunol*. 2001;107(4):703-706.
87. Chandra RK, Hamed A. Cumulative incidence of atopic disorders in high risk infants fed whey hydrolysate, soy, and conventional cow milk formulas. *Ann Allergy*. 1991;67(2 pt 1):129-132.
88. Chandra RK, Singh G, Shridhara B. Effect of feeding whey hydrolysate, soy and conventional cow milk formulas on incidence of atopic disease in high risk infants. *Ann Allergy*. 1989;63(2):102-106.
89. Halmerbauer G, Gartner K, Schier M, et al. Study on the Prevention of Allergy in Children in Europe (SPACE). *Pediatr Allergy Immunol*. 2002;13(suppl 15):47-54.
90. Kajosaari M. Atopy prevention in childhood: the role of diet. *Pediatr Allergy Immunol*. 1994;5(6) (suppl):26-28.
91. Hattevig G, Kjellman B, Sigurs N, Björkstén B, Kjellman NI. Effect of maternal avoidance of eggs, cow's milk and fish during lactation upon allergic manifestations in infants. *Clin Exp Allergy*. 1989;19(1):27-32.
92. Sigurs N, Hattevig G, Kjellman B. Maternal avoidance of eggs, cow's milk, and fish during lactation. *Pediatrics*. 1992;89(4 pt 2):735-739.
93. Filipiak B, Zutavern A, Koletzko S, et al. Solid food introduction in relation to eczema. *J Pediatr*. 2007; 151(4):352-358.
94. Bardare M, Vaccari A, Allievi E, et al. Influence of dietary manipulation on incidence of atopic disease in infants at risk. *Ann Allergy*. 1993;71(4):366-371.
95. Schoetzau A, Filipiak-Pittroff B, Franke K, et al. Effect of exclusive breast-feeding and early solid food avoidance on the incidence of atopic dermatitis in high-risk infants at 1 year of age. *Pediatr Allergy Immunol*. 2002;13(4):234-242.
96. von Berg A, Filipiak-Pittroff B, Kramer U, et al. Preventive effect of hydrolyzed infant formulas persists until age 6 years. *J Allergy Clin Immunol*. 2008; 121(6):1442-1447.
97. von Berg A, Koletzko S, Filipiak-Pittroff B, et al. Certain hydrolyzed formulas reduce the incidence of atopic dermatitis but not that of asthma. *J Allergy Clin Immunol*. 2007;119(3):718-725.
98. Odelram H, Vanto T, Jacobsen L, Kjellman NI. Whey hydrolysate compared with cow's milk-based formula for weaning at about 6 months of age in high allergy-risk infants. *Allergy*. 1996;51(3):192-195.
99. Szajewska H, Mrukowicz JZ, Stoinska B, Prochowska A. Extensively and partially hydrolysed preterm formulas in the prevention of allergic diseases in preterm infants. *Acta Paediatr*. 2004;93(9):1159-1165.
100. Arslanoglu S, Moro GE, Schmitt J, et al. Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life. *J Nutr*. 2008;138(6):1091-1095.
101. Rautava S, Kalliomäki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. *J Allergy Clin Immunol*. 2002;109(1):119-121.
102. Huurre A, Laitinen K, Rautava S, et al. Impact of maternal atopy and probiotic supplementation during pregnancy on infant sensitization. *Clin Exp Allergy*. 2008;38(8):1342-1348.
103. Kuitunen M, Kukkonen K, Juntunen-Backman K, et al. Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort. *J Allergy Clin Immunol*. 2009; 123(2):335-341.
104. Kukkonen K, Savilahti E, Haahtela T, et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases. *J Allergy Clin Immunol*. 2007;119(1):192-198.
105. Abrahamsson TR, Jakobsson T, Böttcher MF, et al. Probiotics in prevention of IgE-associated eczema. *J Allergy Clin Immunol*. 2007;119(5):1174-1180.
106. de Jong MH, Scharp-Van Der Linden VT, Aalberse R, et al. The effect of brief neonatal exposure to cows' milk on atopic symptoms up to age 5. *Arch Dis Child*. 2002;86(5):365-369.
107. de Jong MH, Scharp-van der Linden VT, Aalberse RC, et al. Randomised controlled trial of brief neonatal exposure to cows' milk on the development of atopy. *Arch Dis Child*. 1998;79(2):126-130.
108. Lindfors AT, Danielsson L, Enocksson E, et al. Allergic symptoms up to 4-6 years of age in children given cow milk neonatally. *Allergy*. 1992;47(3):207-211.
109. Kvénshagen B, Halvorsen R, Jacobsen M. Adverse reactions to milk in infants. *Acta Paediatr*. 2008; 97(2):196-200.
110. Laubereau B, Brockow I, Zirnigil A, et al. Effect of breast-feeding on the development of atopic dermatitis during the first 3 years of life. *J Pediatr*. 2004; 144(5):602-607.
111. Liu H. In the United States, black male children have an increased risk of food allergy: results from NHANES 2005-2006. Paper presented at: Annual Meeting of the American Academy of Allergy, Asthma, and Immunology; March 13-17, 2009; Washington, DC.
112. Mudd KE, Driggers SK, Matsui EC, Wood RA. Home introduction of baked milk in children with a history of milk allergy. Abstract presented at: Annual Meeting of the American Academy of Allergy, Asthma, and Immunology; February 26-March 2, 2010; New Orleans, LA. Abstract 52.
113. Bird JA, Pons L, Kulis M, et al. Double-blinded, placebo-controlled Sublingual Immunotherapy (SLIT) trial for peanut allergy. Abstract presented at: Annual Meeting of the American Academy of Allergy, Asthma, and Immunology; February 26-March 2, 2010; New Orleans, LA. Abstract 20.

Supplementary Table S1. Topical Drugs for Atopic Dermatitis

Drug	Formulation	Dose	Comments
CALCINERIU INHIBITORS			
Pimecrolimus 1% (Elidel®)	1% Cream – 30, 60, 100gm	BID	
Tacrolimus 0.03%(Protopic®)	0.03% Ointment – 30, 60, 100gm	BID	
Tacrolimus 0.1% (Protopic®)	0.1% Ointment – 30, 60, 100gm	BID	
CORTICOSTEROIDS Very High Potency			It is recommended that patients on very high potency steroids not be discontinued abruptly; switch to lower potency agent. Treatment duration for most very high potency steroids should not exceed 2 weeks, per FDA-approved labeling Occlusive dressings should be avoided with very high potency corticosteroids Avoid use on face, groin, armpits, or skinfolds due to striae and atrophy Symptoms of adrenal suppression include weakness, weight loss, hypotension, and gastrointestinal distress
Betamethasone dipropionate augmented 0.05% (Diprolene®)	Oint – 15, 45, 50gm Gel – 15, 50gm Oint – 30, 60ml	QD to BID	
Clobetasol propionate 0.05% (all formulations) (Cormax®) (Clobex®) (Olux®) (Temovate®)	0.05% (Cream, Oint, Gel,) – 15, 30, 45, 60gm 0.05% (Cream Emollinet) – 15, 30, 60gm 0.05% Foam – 50, 100gm 0.05% Lotion – 30, 59, 118ml 0.05% Shampoo – 118ml 0.05% Scalp application – 25, 50ml 0.05% Spray – 59, 125ml	QD (shampoo) BID	Clobetasol may cause HPA axis suppression at doses as low as 2gm daily
Fluocinonide 0.1% (Vanos®)	Cream (30,60, 120gm)	QD to BID	Total dose should not exceed 50gms or 50ml per week because of the potential for adrenal suppression
Halobetasol propionate 0.05% (Ultravate®)	Cream/Oint - 15, 50gm	QD to BID	

Drug	Formulation	Dose	Comments
High Potency			Occlusive Dressings should be used with caution May be used on scalp, trunk, hands, and feet Avoid use on face or intertriginous areas due to striae Do not use occlusive dressings in augmented betamethasone dipropionate or betamethasone dipropionate treatment
Amcinonide 0.1% (all formulations)	0.1% Oint/Cream – 15, 30, 60gm 0.1% Lotion – 60ml	BID to TID	
Betamethasone dipropionate 0.05% augmented (Diprolene AF®)	0.05% Cream – 15, 50gm	BID	
Betamethasone dipropionate 0.05%	0.05% Oint/Cream – 15, 45gm	BID	
Desoximetasone 0.25% (Topicort®)	0.25% Cream/Oint – 15, 60gm		
Desoximetasone 0.05%	0.05% Gel – 15, 60gm	BID	
Diflorasone diacetate 0.05%	0.05% Cream – 15, 30, 60gm	QD to QID	
Diflorasone diacetate emollient 0.05% (Psorcon E®)	0.05% Cream – 30, 60gm	QD to TID	
Fluocinonide 0.05% (Lidex®)	0.05% Cream – 15, 30, 60, 120gm 0.05% Gel – 15, 30, 60gm 0.05% Oint – 15, 30, 60gm 0.05% Soln – 20, 60mL 0.05% Cream (emulsified base) – 15, 30, 60gm	BID to QID	
Halcinonide 0.1% (Halog®)	0.1 % Cream – 15, 30, 60gm 0.1% Oint – 30, 60gm 0.1% Soln – 60ml	BID to TID	
Mometasone 0.1% (Elocon®)	0.1% Oint/Cream Lotion (15, 45gm)	QD	
Triamcinolone acetonide 0.5%	0.5% Oint/Cream – 15gm	BID to QID	
Medium-High Potency			
Amcinonide 0.1%	0.1% Oint/Cream – 15, 30, 60gm 0.1% Lotion – 60ml	BID to TID	
Betamethasone dipropionate 0.05% (Alphatrex®)	Cream Gel	BID	
Betamethasone valerate 0.1%	Oint	QD to TID	
Desoximetasone 0.05%	0.05% Cream – 15, 60gm	BID	
Diflorasone diacetate 0.05%	0.05% Cream – 30, 60gm	QD to QID	
Fluocinonide emollient 0.05% (Lidex E®)	0.05% Cream – 15, 30, 60gm	BID to QID	
Fluticasone propionate 0.05% (Cutivate®)	0.05% Oint – 15, 30, 60gm 0.05% Cream – 15, 30, 60gm	QD to BID	
Triamcinolone acetonide 0.1% (Kenalog®)	Oint Oint	BID to QID	
Triamcinolone acetonide 0.5%	Cream		

Drug	Formulation	Dose	Comments
Medium Potency			May be used on scalp or trunk extremities Non-flourinated products may be used on the face, axillae, and groin Stripping of the epidermis and purpura has been reported with use of flurandrenolide tape dressings Do not use occlusive dressings in mometasone treatment
Betamethasone valerate 0.12% (Luxiq®)	0.12% Foam – 50, 100, 150gm cans	BID	
Fluocinolone acetonide 0.025% (Synalar®)	0.025% Cream – 15, 60gm 0.025% Oint – 15, 60gm	TID to QID	
Hydrocortisone valerate 0.2% (Westcort®)	0.2% Cream/Oint – 15, 45, 60gm	BID to TID	
Mometasone furoate 0.1% (Elocon®)	0.1% Cream – 15, 45gm	QD	
Triamcinolone acetonide 0.1% (Kenalog®)	0.1% Cream – 15, 30, 80, 90, 454, 2268gm 0.1% Oint – 15, 30, 80, 454gm	BID to QID	
Medium-Low Potency			
Betamethasone dipropionate 0.05%	0.05% Lotion – 60ml	BID	
Betamethasone valerate 0.1%	0.1% Cream – 15, 45gm 0.1% Lotion – 60ml	QD to TID	
Desonide 0.05% (Desowen®)	0.05% Oint – 15, 60gm	BID to TID	
Fluocinolone acetonide 0.025% (Synalar®)	0.025% Cream – 15, 60gm 0.025% Oint – 15, 60gm	TID to QID	
Flurandrenolide 0.05% (Cordran®) Flurandrenolide 0.05% (Cordran SP®)	0.05% Lotion – 15, 60ml 0.05% Cream – 15, 30, 60gm	BID to TID	
Fluticasone propionate 0.05% (Cutivate®)	0.05% Cream – 15, 30, 60gm 0.05% Oint – 15, 30, 60gm	QD to BID	
Hydrocortisone butyrate 0.1% (Locoid®) (Locoid Lipocream®)	0.1% Cream/Oint – 15, 45gm 0.1% Soln – 20, 60ml	BID to TID	
Hydrocortisone valerate 0.2% (Westcort)	0.2% Cream/Oint – 15, 45, 60gm	BID to TID	
Prednicarbate 0.1% (Dermatop®)	Cream, oint		
Triamcinolone acetonide 0.025%	0.025% Oint/Cream – 15, 80, 454gm 0.025% Lotion – 60ml	BID to QID	
Triamcinolone acetonide 0.1% (Kenalog®)	0.1% Lotion – 60ml 0.1% Cream – 15, 30, 80, 90, 454, 2268gm 0.1% Oint – 15, 30, 80, 454gm	BID to QID	

Drug	Formulation	Dose	Comments
Low Potency			Hydrocortisone is available by prescription and OTC. The 2.5% strength is prescription; some 1% formulations are prescription while others are OTC Low potency agents are recommended in children or in patients requiring large areas of the body to be covered Low potency steroids should be used on body sites that are most susceptible to steroid damage (i.e. face, skin folds)
Alclometasone dipropionate 0.05% (Aclovate®)	0.05% Oint/Cream – 15, 45, 60gm	BID to TID	
Betamethasone valerate 0.1%	0.1% Lotion – 60ml 0.1% Ointment – 15, 45gm 0.1% Cream – 15, 45gm	QD to TID	
Clocortolone 0.1% (Cloderm®)	0.1% Cream – 15, 45, 90gm	QD to TID	
Desonide 0.05% (Desonate®) (Desowe®) (Verdeso®)	0.05% Cream/Oint – 15, 60gm 0.05% Lotion – 60, 120ml 0.05% Foam – 50, 100gm	BID to QID	
Fluocinolone acetonide 0.01% (Synalar®)	0.01% Cream – 15, 60gm 0.01% Soln – 60ml 0.01% Shampoo – 120ml	QD Shampoo TID to QID Cream, Solution	
Triamcinolone acetonide 0.025% (Kenalog®)	0.025% Oint – 15, 80, 454gm 0.025% Cream – 15, 80, 454gm 0.025% Lotion – 60ml	BID to QID	
Lowest Potency			
Hydrocortisone 0.5% (OTC)	0.5% Cream – 30gm	BID to QID	
Hydrocortisone 1.0% (OTC) (Hytone®)	Cream, oint, lotion Cream	BID to QID	
Hydrocortisone 2.5% (Hytone®)	1% Cream – 15, 30gm 1% Oint – 30gm 1% Lotion – 120ml	BID to QID	